A novel rapid test for detecting antibody responses to Loa loa infections.
Ivermectin-based mass drug administration (MDA) programs have achieved remarkable success towards the elimination of onchocerciasis and lymphatic filariasis. However, their full implementation has been hindered in Central Africa by the occurrence of ivermectin-related severe adverse events (SAEs) in...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-07-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC5531435?pdf=render |
id |
doaj-75e896981e0d41149101d542497e8617 |
---|---|
record_format |
Article |
spelling |
doaj-75e896981e0d41149101d542497e86172020-11-25T01:32:48ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352017-07-01117e000574110.1371/journal.pntd.0005741A novel rapid test for detecting antibody responses to Loa loa infections.Bijan PedramValérie PasquettoPapa M DrameYongchang JiMaria J Gonzalez-MoaRichard K BaldwinThomas B NutmanMarco A BiamonteIvermectin-based mass drug administration (MDA) programs have achieved remarkable success towards the elimination of onchocerciasis and lymphatic filariasis. However, their full implementation has been hindered in Central Africa by the occurrence of ivermectin-related severe adverse events (SAEs) in a subset of individuals with high circulating levels of Loa loa microfilariae. Extending MDA to areas with coincident L. loa infection is problematic, and inexpensive point-of-care tests for L. loa are acutely needed. Herein, we present a lateral flow assay (LFA) to identify subjects with a serological response to Ll-SXP-1, a specific and validated marker of L. loa. The test was evaluated on serum samples from patients infected with L. loa (n = 109) and other helminths (n = 204), as well as on uninfected controls (n = 77). When read with the naked eye, the test was 94% sensitive for L. loa infection and was 100% specific when sera from healthy endemic and non-endemic controls or from those with S. stercoralis infections were used as the comparators. When sera of patients with O. volvulus, W. bancrofti, or M. perstans were used as the comparators, the specificity of the LFA was 82%, 87%, and 88%, respectively. A companion smartphone reader allowed measurement of the test line intensities and establishment of cutoff values. With a cutoff of 600 Units, the assay sensitivity decreased to 71%, but the specificity increased to 96% for O. volvulus, 100% for W. bancrofti, and 100% for M. perstans-infected individuals. The LFA may find applications in refining the current maps of L. loa prevalence, which are needed to eliminate onchocerciasis and lymphatic filariasis from the African continent.http://europepmc.org/articles/PMC5531435?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bijan Pedram Valérie Pasquetto Papa M Drame Yongchang Ji Maria J Gonzalez-Moa Richard K Baldwin Thomas B Nutman Marco A Biamonte |
spellingShingle |
Bijan Pedram Valérie Pasquetto Papa M Drame Yongchang Ji Maria J Gonzalez-Moa Richard K Baldwin Thomas B Nutman Marco A Biamonte A novel rapid test for detecting antibody responses to Loa loa infections. PLoS Neglected Tropical Diseases |
author_facet |
Bijan Pedram Valérie Pasquetto Papa M Drame Yongchang Ji Maria J Gonzalez-Moa Richard K Baldwin Thomas B Nutman Marco A Biamonte |
author_sort |
Bijan Pedram |
title |
A novel rapid test for detecting antibody responses to Loa loa infections. |
title_short |
A novel rapid test for detecting antibody responses to Loa loa infections. |
title_full |
A novel rapid test for detecting antibody responses to Loa loa infections. |
title_fullStr |
A novel rapid test for detecting antibody responses to Loa loa infections. |
title_full_unstemmed |
A novel rapid test for detecting antibody responses to Loa loa infections. |
title_sort |
novel rapid test for detecting antibody responses to loa loa infections. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Neglected Tropical Diseases |
issn |
1935-2727 1935-2735 |
publishDate |
2017-07-01 |
description |
Ivermectin-based mass drug administration (MDA) programs have achieved remarkable success towards the elimination of onchocerciasis and lymphatic filariasis. However, their full implementation has been hindered in Central Africa by the occurrence of ivermectin-related severe adverse events (SAEs) in a subset of individuals with high circulating levels of Loa loa microfilariae. Extending MDA to areas with coincident L. loa infection is problematic, and inexpensive point-of-care tests for L. loa are acutely needed. Herein, we present a lateral flow assay (LFA) to identify subjects with a serological response to Ll-SXP-1, a specific and validated marker of L. loa. The test was evaluated on serum samples from patients infected with L. loa (n = 109) and other helminths (n = 204), as well as on uninfected controls (n = 77). When read with the naked eye, the test was 94% sensitive for L. loa infection and was 100% specific when sera from healthy endemic and non-endemic controls or from those with S. stercoralis infections were used as the comparators. When sera of patients with O. volvulus, W. bancrofti, or M. perstans were used as the comparators, the specificity of the LFA was 82%, 87%, and 88%, respectively. A companion smartphone reader allowed measurement of the test line intensities and establishment of cutoff values. With a cutoff of 600 Units, the assay sensitivity decreased to 71%, but the specificity increased to 96% for O. volvulus, 100% for W. bancrofti, and 100% for M. perstans-infected individuals. The LFA may find applications in refining the current maps of L. loa prevalence, which are needed to eliminate onchocerciasis and lymphatic filariasis from the African continent. |
url |
http://europepmc.org/articles/PMC5531435?pdf=render |
work_keys_str_mv |
AT bijanpedram anovelrapidtestfordetectingantibodyresponsestoloaloainfections AT valeriepasquetto anovelrapidtestfordetectingantibodyresponsestoloaloainfections AT papamdrame anovelrapidtestfordetectingantibodyresponsestoloaloainfections AT yongchangji anovelrapidtestfordetectingantibodyresponsestoloaloainfections AT mariajgonzalezmoa anovelrapidtestfordetectingantibodyresponsestoloaloainfections AT richardkbaldwin anovelrapidtestfordetectingantibodyresponsestoloaloainfections AT thomasbnutman anovelrapidtestfordetectingantibodyresponsestoloaloainfections AT marcoabiamonte anovelrapidtestfordetectingantibodyresponsestoloaloainfections AT bijanpedram novelrapidtestfordetectingantibodyresponsestoloaloainfections AT valeriepasquetto novelrapidtestfordetectingantibodyresponsestoloaloainfections AT papamdrame novelrapidtestfordetectingantibodyresponsestoloaloainfections AT yongchangji novelrapidtestfordetectingantibodyresponsestoloaloainfections AT mariajgonzalezmoa novelrapidtestfordetectingantibodyresponsestoloaloainfections AT richardkbaldwin novelrapidtestfordetectingantibodyresponsestoloaloainfections AT thomasbnutman novelrapidtestfordetectingantibodyresponsestoloaloainfections AT marcoabiamonte novelrapidtestfordetectingantibodyresponsestoloaloainfections |
_version_ |
1725079758519140352 |